Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Near-Infrared Light Triggered Upconversion Optogenetic Nanosystem for Cancer Therapy.

ACS nano·2017

Same author

Non-contact method to freely control the radiation patterns of antenna with multi-folded transformation optics.

Scientific reports·2017

Same author

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

Clinical drug investigation·2017

Same author

Improving Performance of Breast Cancer Risk Prediction by Incorporating Optical Density Image Feature Analysis: An Assessment.

Academic radiology·2017

Same author

Preliminary study on ultrasound-guided prostate biopsy specimen scores.

Experimental and therapeutic medicine·2017

Same author

Characterization of Continuous and Pulsed Emission modes of a Hybrid Micro Focus X-ray Source for Medical Imaging Applications.

Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment·2017

Search research articles

Related Experiment Video

Updated: Jun 16, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Receptor-targeted Lactococcus lactis mitigate Clostridioides difficile infection.

Yue Zhang¹, Wei Sun², Hao Wu³

¹Department of Pharmaceutical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, PR China.

Microbiological Research

|June 13, 2025

Summary

Engineered Lactococcus lactis effectively targets Clostridioides difficile infection by producing nisin. Lipid-coated bacteria show enhanced therapeutic potential against recurrent CDI, outperforming current treatments.

Keywords:

Adhesion Clostridioides difficile infection Lactococcus lactis Nisin RCDI ROS-responsive lipid membrane

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016

Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016

Published on: June 23, 2023

Related Experiment Videos

Last Updated: Jun 16, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016

Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016

Published on: June 23, 2023

Area of Science:

Microbiology
Biotechnology
Gastroenterology

Background:

Engineered bacteria are crucial for colorectal disease management.
Lactococcus lactis produces nisin to inhibit Clostridioides difficile.
Limitations include insufficient nisin production, lack of targeted release, and weak colonization.

Purpose of the Study:

To engineer L. lactis for enhanced adherence and therapeutic efficacy.
To develop a targeted delivery system for nisin production.
To evaluate the efficacy against Clostridioides difficile infection (CDI) and recurrent CDI (rCDI).

Main Methods:

Engineered L. lactis (Lla+) expressing C. difficile adhesion protein Cwp8 for increased adherence.
Created lipid membrane-coated L. lactis (LCL) using ROS-responsive lipid membrane for encapsulation.
Evaluated in vitro and in vivo efficacy in cell models and mouse models of intestinal inflammation.

Main Results:

Lla+ showed a 1.3-fold increase in adhesion compared to wild-type L. lactis.
LCL demonstrated targeted nisin release in response to inflammatory stimuli and C. difficile.
LCL significantly reduced C. difficile survival by 60% and outperformed fidaxomicin in recurrent CDI models.

Conclusions:

Encapsulation approach serves as a viable delivery platform for targeting inflamed intestines.
Engineered L. lactis offers a promising therapeutic strategy for CDI and rCDI.
Probiotics can be expanded as effective pharmaceuticals for gastrointestinal diseases.